Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes
The experimental triple-agonist also improved diabetes control and eased knee pain and sleep-apnea episodes in separate trials.
- New studies published in The Lancet and the New England Journal of Medicine show Eli Lilly's experimental drug retatrutide leads to meaningful weight loss in patients with Type 2 diabetes and obesity.
- Unlike existing GLP-1 drugs, retatrutide acts as a triple agonist by targeting three metabolic hormone receptors—GLP-1, GIP, and glucagon—to manage appetite and blood sugar while accelerating metabolism.
- Trial results indicate patients with Type 2 diabetes lost up to 60 pounds, or about 23% of their body weight, while those without diabetes lost up to 70 pounds, or 25% of their body weight, after 80 weeks.
- Beyond weight reduction, the drug improved blood sugar control and helped patients with obstructive sleep apnea and knee arthritis; Dr. Susan Spratt of Duke Health called it "truly an advance in diabetes care."
- Eli Lilly plans to file for approval with the Food and Drug Administration early next year, though researchers noted the trials lacked head-to-head comparisons with other existing obesity medications.
11 Articles
11 Articles
Lilly’s experimental drug cuts weight by 21% in diabetes trial
Sept 29 (Reuters) - Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial. (Reporting by Kamal Choudhury in ...
The retatrutide, a new drug for obesity and diabetes still under development by Eli Lilly (the same manufacturer of the Mounjaro), provided substantial weight loss and reductions in glycated hemoglobin (an important target in diabetes control).The new data, presented at the 62nd Annual Meeting of the European Diabetes Study Association (EASD) in Milan, Italy, and published simultaneously in the scientific journal The Lancet, refer to the TRIUMPH…
People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
Eli Lilly’s highly anticipated GLP-1 drug retatrutide helped people with Type 2 diabetes lose up to 60 pounds, or about 23% of their body weight, according to late-stage trial results published Tuesday in The Lancet.
The Independent
The Independent (US)Fresh hope for diabetics as new drug helps them shed a quarter of their bodyweight
The large-scale trial took place across 92 sites in eight countries
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
